GRDN logo

Guardian Pharmacy Services, Inc. (GRDN) Hisse Analizi

Yalnızca bilgilendirme amaçlıdır. Finansal tavsiye değildir. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

GRDN, 35.40$ (piyasa değeri 3B) fiyatla Healthcare işi olan Guardian Pharmacy Services, Inc.'i temsil ediyor. Hisse senedi, 9 kantitatif KPI'ya dayalı olarak orta dereceli bir derecelendirme olan 51/100 puan alıyor.

Son analiz: 5 Şub 2026
51/100 AI Puanı Hedef $38.00 (+7.3%) PD 3B Hacim 350K

Guardian Pharmacy Services, Inc. (GRDN) Sağlık ve Boru Hattı Genel Bakışı

CEOFred Burke
Çalışanlar3400
MerkezAtlanta, US
Halka Arz Yılı2016
SektörHealthcare

Guardian Pharmacy Services delivers tailored pharmacy solutions to long-term care facilities, leveraging technology and data analytics to optimize medication management and clinical outcomes, positioning them as a key player in the evolving healthcare landscape with a P/E ratio of 50.75.

Veri Kaynağı | Finansal Veriler Kantitatif Analiz NASDAQ Analiz: 5 Şub 2026

Yatırım Tezi

Guardian Pharmacy Services presents a notable research candidate due to its strategic focus on the underserved market of lower acuity long-term care facilities. The company's technology-enabled solutions, including Guardian Compass and GuardianShield Programs, drive efficiency and improve clinical outcomes, enhancing its value proposition to LTCFs. With a market capitalization of $2.08 billion and a profit margin of 2.9%, Guardian Pharmacy Services demonstrates financial stability and growth potential. Key value drivers include the increasing demand for specialized pharmacy services in LTCFs, the company's ability to leverage data analytics to optimize operations, and its established presence in a fragmented market. Upcoming catalysts include potential expansion into new geographic markets and the development of innovative service offerings. The company's beta of 0.96 suggests lower volatility compared to the broader market, making it a noteworthy option for risk-averse investors.

FMP finansallarına ve nicel analizine dayanmaktadır

Temel Önemli Noktalar

  • Market capitalization of $2.08 billion reflects substantial investor confidence in Guardian Pharmacy Services' market position and growth prospects.
  • P/E ratio of 50.75 indicates investor expectations for future earnings growth, driven by increasing demand for specialized pharmacy services.
  • Gross margin of 19.7% demonstrates the company's ability to maintain profitability while delivering value-added services to long-term care facilities.
  • A beta of 0.96 suggests the stock is slightly less volatile than the market, offering a degree of stability in investment portfolios.
  • The company's focus on technology-enabled solutions, such as Guardian Compass, differentiates it from competitors and enhances its operational efficiency.

Rakipler & Benzerleri

Güçlü Yönler

  • Technology-enabled solutions enhance efficiency and improve clinical outcomes.
  • Focus on lower acuity LTCFs allows for specialized service offerings.
  • Established relationships with LTCF operators provide a stable customer base.
  • Data-driven insights enable continuous improvement and optimization.

Zayıflıklar

  • Reliance on LTCF reimbursement models exposes the company to regulatory risks.
  • Limited geographic diversification may constrain growth potential.
  • Profit margin of 2.9% is relatively low compared to industry peers.
  • High P/E ratio of 50.75 suggests the stock may be overvalued.

Katalizörler

  • Upcoming: Potential acquisitions of smaller pharmacy providers to expand market share.
  • Ongoing: Increasing demand for specialized pharmacy services in LTCFs due to the aging population.
  • Ongoing: Continued adoption of technology-enabled solutions by LTCFs to improve efficiency and reduce costs.
  • Upcoming: Development and launch of new service offerings, such as specialized medication management programs.

Riskler

  • Potential: Changes in government regulations and reimbursement policies could negatively impact revenue.
  • Potential: Economic downturns may reduce occupancy rates in LTCFs, leading to lower demand for pharmacy services.
  • Ongoing: Increasing competition from larger pharmacy chains and specialized providers.
  • Potential: Cybersecurity threats and data breaches could compromise patient information and damage the company's reputation.

Büyüme Fırsatları

  • Expansion into new geographic markets represents a significant growth opportunity for Guardian Pharmacy Services. By extending its reach beyond its current footprint, the company can tap into underserved markets and increase its customer base. The market size for LTC pharmacy services is estimated at over $20 billion annually, providing ample room for growth. This expansion can be achieved through strategic acquisitions or organic growth, with a timeline of 3-5 years for significant market penetration. The company's established infrastructure and expertise in serving LTCFs provide a competitive advantage in entering new regions.
  • Development of innovative service offerings, such as specialized medication management programs for specific conditions (e.g., dementia, diabetes), can drive revenue growth and enhance customer loyalty. The market for specialized pharmacy services is growing rapidly, with a projected annual growth rate of 8-10%. Guardian Pharmacy Services can leverage its data analytics capabilities to identify unmet needs and develop tailored solutions. This initiative can be implemented within 1-2 years, with ongoing refinement and expansion based on market feedback. The company's clinical expertise and technology platform provide a strong foundation for innovation.
  • Strategic partnerships with LTCF operators can create synergistic opportunities and drive customer acquisition. By collaborating with leading LTCF chains, Guardian Pharmacy Services can gain access to a large pool of potential customers and streamline its sales and marketing efforts. The market for LTCF services is highly fragmented, with numerous regional and national operators. These partnerships can be established within 6-12 months, with ongoing collaboration to optimize service delivery and enhance customer satisfaction. The company's reputation for quality and reliability makes it an attractive partner for LTCF operators.
  • Leveraging data analytics to improve medication adherence and reduce healthcare costs can create value for both LTCFs and payers. By identifying patients at risk of non-adherence and implementing targeted interventions, Guardian Pharmacy Services can improve clinical outcomes and reduce hospital readmissions. The market for medication adherence solutions is growing rapidly, driven by the increasing focus on value-based care. This initiative can be implemented within 1-2 years, with ongoing monitoring and refinement based on patient outcomes. The company's data analytics platform and clinical expertise provide a competitive advantage in this area.
  • Expanding into the specialty pharmacy market for LTCFs represents a high-growth opportunity. Specialty medications, such as biologics and infused therapies, are increasingly used in LTCFs to treat complex conditions. The market for specialty pharmacy services is growing at a double-digit rate, driven by the increasing prevalence of chronic diseases and the availability of new therapies. Guardian Pharmacy Services can leverage its existing infrastructure and expertise to enter this market, with a timeline of 2-3 years for significant market penetration. The company's focus on technology and data analytics will be critical for managing the complexities of specialty pharmacy.

Fırsatlar

  • Expansion into new geographic markets can drive revenue growth.
  • Development of innovative service offerings can enhance customer loyalty.
  • Strategic partnerships with LTCF operators can create synergistic opportunities.
  • Leveraging data analytics to improve medication adherence can reduce healthcare costs.

Tehditler

  • Increasing competition from larger pharmacy chains and specialized providers.
  • Changes in government regulations and reimbursement policies.
  • Economic downturns may reduce occupancy rates in LTCFs.
  • Cybersecurity threats and data breaches could compromise patient information.

Rekabet Avantajları

  • Specialized Focus: Concentrating on lower acuity LTCFs allows for tailored service offerings and deeper market penetration.
  • Technology-Enabled Solutions: Guardian Compass and GuardianShield Programs provide a competitive edge through data-driven insights and enhanced safety protocols.
  • Established Relationships: Long-standing partnerships with LTCFs create a stable revenue stream and barriers to entry for new competitors.
  • Scalable Infrastructure: The company's infrastructure is designed to efficiently serve a growing number of LTCFs across multiple geographic locations.

GRDN Hakkında

Founded in 2003 and headquartered in Atlanta, Georgia, Guardian Pharmacy Services, Inc. emerged to address the unique pharmaceutical needs of residents in long-term health care facilities (LTCFs). Recognizing the increasing demand for specialized pharmacy services within this sector, the company developed a comprehensive suite of technology-enabled solutions designed to improve medication management and clinical outcomes. Guardian Pharmacy Services primarily caters to lower acuity LTCFs, including assisted living facilities, behavioral health facilities, and group homes. Their core offerings encompass individualized clinical support, precise drug dispensing, and efficient administration capabilities, all tailored to the specific requirements of each facility and its residents. A key differentiator is Guardian Compass, a proprietary platform that utilizes data from the company's data warehouse to provide local pharmacies with actionable insights for business planning, tracking, and optimization. Complementing this is the GuardianShield Programs, designed to enhance safety and compliance within LTCFs. With 3,400 employees, Guardian Pharmacy Services has established a significant presence in the US market, providing a vital link between pharmaceutical care and the well-being of vulnerable populations within long-term care settings. The company's commitment to innovation and data-driven solutions positions it as a leader in the evolving landscape of specialized pharmacy services.

Ne Yaparlar

  • Provide technology-enabled pharmacy services to long-term care facilities (LTCFs).
  • Offer individualized clinical support to residents in LTCFs.
  • Dispense medications accurately and efficiently.
  • Administer medications according to prescribed regimens.
  • Serve residents in lower acuity LTCFs, such as assisted living facilities.
  • Utilize Guardian Compass for data-driven business planning and optimization.
  • Implement GuardianShield Programs to enhance safety and compliance in LTCFs.

İş Modeli

  • Generate revenue through the dispensing of prescription medications to residents in LTCFs.
  • Provide clinical consulting services to LTCFs, optimizing medication management and patient care.
  • Offer technology solutions, such as Guardian Compass, to enhance operational efficiency for LTCFs.
  • Establish contracts with LTCFs to provide comprehensive pharmacy services.

Sektör Bağlamı

Guardian Pharmacy Services operates within the medical distribution industry, a segment of the healthcare sector experiencing steady growth due to the aging population and increasing demand for long-term care services. The market is characterized by a mix of large national players and smaller regional providers. Guardian Pharmacy Services distinguishes itself through its focus on lower acuity LTCFs and its technology-driven approach. The industry is subject to regulatory scrutiny and evolving reimbursement models, requiring companies to adapt and innovate to maintain profitability. The company's commitment to data analytics and customized solutions positions it favorably within this competitive landscape, allowing it to capture market share and drive growth.

Kilit Müşteriler

  • Assisted living facilities (ALFs)
  • Behavioral health facilities
  • Group homes
  • Other lower acuity long-term care facilities
AI Güveni: 73% Güncellendi: 5 Şub 2026

Finansallar

Grafik & Bilgi

Guardian Pharmacy Services, Inc. (GRDN) hisse senedi fiyatı: $35.40 (-1.10, -3.01%)

Son Haberler

Analist Konsensüsü

Fikir Birliği Derecelendirmesi

GRDN için Benzinga, Yahoo Finance ve Finnhub'dan toplanan Al/Tut/Sat önerileri.

Fiyat Hedefleri

Konsensüs hedefi: $38.00

MoonshotScore

51/100

Bu puan ne anlama geliyor?

MoonshotScore, GRDN'ın büyüme potansiyelini inovasyon, pazar yıkımı, finansal sağlık ve momentum dahil olmak üzere birden fazla faktörde 0-100 ölçeğinde derecelendirir.

En Son Guardian Pharmacy Services, Inc. Analizi

Yatırımcılar Guardian Pharmacy Services, Inc. (GRDN) Hakkında Ne Soruyor

GRDN için değerlendirilmesi gereken temel faktörler nelerdir?

Guardian Pharmacy Services, Inc. (GRDN) şu anda yapay zeka skoru 51/100, orta puanı gösteriyor. Hisse 45.5x F/K oranıyla işlem görüyor, S&P 500 ortalamasının (~20-25x) üzerinde, yüksek büyüme beklentilerine işaret ediyor. Analist hedefi $38.00 ($35.40'dan +7%). Temel güçlü yan: Technology-enabled solutions enhance efficiency and improve clinical outcomes.. İzlenmesi gereken birincil risk: Potential: Changes in government regulations and reimbursement policies could negatively impact revenue.. Bu bir finansal tavsiye değildir.

GRDN MoonshotScore'u nedir?

GRDN şu anda MoonshotScore'da 51/100 (Derece C) alıyor, bu da orta derecelendirme gösteriyor. Puan, 9 kantitatif KPI genelinde büyüme potansiyelini, finansal sağlığı, piyasa momentumunu ve risk faktörlerini değerlendirir. En son piyasa verileri kullanılarak günlük olarak yeniden hesaplanır. Bu puan yalnızca bilgilendirme amaçlıdır.

GRDN verileri ne sıklıkla güncellenir?

GRDN fiyatları ABD piyasa saatleri (hafta içi 9:30-16:00 ET) sırasında gerçek zamanlı olarak güncellenir. Temeller, üç aylık veya yıllık beyanlardan sonra yenilenir. Analist derecelendirmeleri ve yapay zeka öngörüleri günlük olarak güncellenir. Haberler, finans kaynaklarından sürekli olarak toplanır.

Analistler GRDN hakkında ne diyor?

Analistler, GRDN için $38.00 konsensüs fiyat hedefi belirledi, bu mevcut fiyattan ($35.40) yukarı yönlü %7 potansiyeli temsil ediyor. Kapsam, al, tut ve sat derecelendirmelerini, kazanç tahminlerini ve son yükseltmeleri veya düşürmeleri içerir. Tüm ayrıntılar için bu sayfadaki Analist Konsensüsü bölümüne bakın.

GRDN'a yatırım yapmanın riskleri nelerdir?

GRDN için risk kategorileri arasında piyasa riski, şirkete özgü risk (yönetim, rekabet), finansal risk (borç, nakit yakımı) ve makroekonomik risk (oranlar, enflasyon) yer alır. Yapay zeka analizi tarafından belirlenen önemli bir risk: Potential: Changes in government regulations and reimbursement policies could negatively impact revenue.. 1,0'ın üzerindeki beta, S&P 500'den daha yüksek volatiliteyi gösterir. 45.5x F/K oranıyla, büyüme beklentileri karşılanamazsa değerleme riski taşıyor. Ayrıntılar için bu sayfadaki Risk Faktörleri bölümünü inceleyin. Tüm yatırımlar kayıp riski taşır.

GRDN'ın P/E oranı nedir?

Guardian Pharmacy Services, Inc. (GRDN)'nın son P/E oranı 45.5, ki bu da piyasa ortalamasının üzerinde, bu da yüksek büyüme beklentilerini gösterebilir. P/E (fiyat-kazanç) oranı, hisse senedi fiyatını hisse başına kazancıyla karşılaştırır. Bağlam için bunu sektördeki emsallerle ve S&P 500 ortalamasıyla (~20-25x) karşılaştırın. Yüksek bir P/E beklenen gelecekteki büyümeyi yansıtabilirken, düşük bir P/E değer düşüklüğünü veya azalan kazançları gösterebilir. Bu bir finansal tavsiye değildir.

GRDN aşırı değerli mi, yoksa düşük değerli mi?

Guardian Pharmacy Services, Inc. (GRDN)'ın aşırı değerli mi yoksa düşük değerli mi olduğunu belirlemek, birden fazla metriği incelemeyi gerektirir. P/E oranı 45.5. Analist hedefi $38.00 (mevcut fiyattan +7%), analistlerin hisse senedini adil değere yakın gördüğünü gösteriyor. Kapsamlı bir görünüm için değerleme oranlarını (P/E, P/S, EV/EBITDA) sektördeki emsallerle karşılaştırın. Bu bir finansal tavsiye değildir.

GRDN'ın temettü verimi nedir?

Guardian Pharmacy Services, Inc. (GRDN) şu anda düzenli bir temettü ödemiyor veya temettü verimi verileri mevcut değil. Büyüme odaklı şirketler genellikle temettü ödemek yerine karları yeniden yatırır. En son temettü bilgileri ve ödeme geçmişi için Finansallar sekmesini kontrol edin.

Sorumluluk reddi: Bu içerik yalnızca bilgilendirme amaçlıdır ve yatırım tavsiyesi teşkil etmez. Her zaman kendi araştırmanızı yapın ve bir finans uzmanına danışın.

Resmi Kaynaklar

Analiz güncellendi AI Puanı günlük olarak yenilenir
Veri Kaynakları ve Metodoloji
Piyasa verileri Financial Modeling Prep ve Yahoo Finance tarafından sağlanmaktadır. AI analizi Stock Expert AI tescilli algoritmaları ile yapılmaktadır. Teknik göstergeler endüstri standardı hesaplamalarla üretilmektedir. Son güncelleme: .

Veriler yalnızca bilgilendirme amaçlı sağlanmıştır.

Analiz Notları
  • Financial data is based on available information and may be subject to change.
  • Market analysis is based on current industry trends and may not accurately predict future outcomes.
  • This dossier is for informational purposes only and does not constitute investment advice.
Veri Kaynakları

Popüler Hisseler